Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
📰 Hand Held Dynamometry News
Hand Held Dynamometry News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Hand Held Dynamometry. Real-time updates on events, politics, business and more.
Biogen Inc.: Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
BIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral sclerosis (ALS), did not show clinical benefit; clinical program will be discontinuedBiogen and Ionis remain
Source: finanznachrichten.de